CHMP Upholds Negative Opinion For The EU Application For Cimzia(R) In The Treatment Of Crohn’s Disease
Apr 2nd 2008Drug InformationCrohn
UCB announced that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia® (certolizumab pegol) in the treatment of patients with Crohn’s disease, a chronic and debilitating inflammatory disease.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
